Ligand Pharmaceuticals Files 8-K on Financials

TL;DR

LGND filed an 8-K on Nov 7th detailing financial results. Check it for the latest on their performance.

AI Summary

Ligand Pharmaceuticals Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending November 7, 2024. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides an update on Ligand Pharmaceuticals' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.

Key Players & Entities

• LIGAND PHARMACEUTICALS INC (company) — Filer
• Delaware (jurisdiction) — State of Incorporation
• November 7, 2024 (date) — Date of Report
• San Diego, California (location) — Business Address

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market

Filing Documents

• lgnd-20241107.htm (8-K) — 25KB
• q32024earningsrelease_ex991.htm (EX-99.1) — 241KB
• newligandlogo.jpg (GRAPHIC) — 11KB
• 0000886163-24-000074.txt ( ) — 426KB
• lgnd-20241107.xsd (EX-101.SCH) — 2KB
• lgnd-20241107_lab.xml (EX-101.LAB) — 21KB
• lgnd-20241107_pre.xml (EX-101.PRE) — 12KB
• lgnd-20241107_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 7, 2024, Ligand Pharmaceuticals Incorporated (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated November 7, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: November 7, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR